Education
About Us
Working with TipRanks
Follow Us
Arecor Therapeutics PLC (GB:AREC)
LSE:AREC
AREC Stock Chart & Stats
85.00p
-0.75p(-1.01%)
At close: 4:00 PM EST
85.00p
-0.75p(-1.01%)
Day’s Range― - ―
52-Week Range35.40p - 100.00p
Previous CloseN/A
Volume5.49K
Average Volume (3M)40.10K
Market Cap
£27.37M
Enterprise Value25.68M
Total Cash (Recent Filing)£1.89M
Total Debt (Recent Filing)£173.00K
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding37,756,600
10 Day Avg. Volume67,644
30 Day Avg. Volume40,099
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)4.59
Price to Sales (P/S)4.86
P/FCF Ratio-2.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Partnerships & IP ExpansionPartnerships and an expanding IP portfolio create durable commercial pathways via licensing, milestones and royalties, reducing single-product risk. Stronger board governance supports execution and access to partners, improving long-term dealflow and funding diversification.
Consistent Revenue GrowthSustained revenue growth signals product validation and traction with partners, strengthening recurring licensing and milestone income potential. Over months this trend can expand bargaining power, improve partner reinvestment, and shorten the path to stable commercial revenue streams.
Strong Equity Funding PositionA solid equity base reduces near-term insolvency risk and provides non-debt flexibility to fund R&D and partnerships. This structural capital cushion supports continued development programs and negotiations without immediate reliance on high-cost external borrowing.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows indicate ongoing cash burn that will require external financing or dilutive raises. Over a multi-month horizon this constrains strategic flexibility, increases financing risk, and can delay commercialization or scale-up of partnered products.
Consistent Net Losses And Margin DeclineOngoing net losses and a decline in gross margin suggest rising costs or pricing pressures that undermine long-term profitability. If margins don't stabilize, the company will struggle to self-fund R&D and commercialization, increasing dependence on external capital and partnership terms.
Shrinking Asset Base And Concerning Leverage MetricsA shrinking asset base paired with a problematic debt-to-equity metric reduces balance sheet resilience. If cash reserves decline further, the company may face higher borrowing costs or limited ability to support trials and launches, pressuring long-term operational continuity.
Arecor Therapeutics PLC News
AREC FAQ
What was Arecor Therapeutics PLC’s price range in the past 12 months?
Arecor Therapeutics PLC lowest share price was 35.40p and its highest was 100.00p in the past 12 months.
What is Arecor Therapeutics PLC’s market cap?
Arecor Therapeutics PLC’s market cap is £27.37M.
When is Arecor Therapeutics PLC’s upcoming earnings report date?
Arecor Therapeutics PLC’s upcoming earnings report date is Apr 28, 2026 which is in 69 days.
How were Arecor Therapeutics PLC’s earnings last quarter?
Arecor Therapeutics PLC released its earnings results on Sep 25, 2025. The company reported -0.07p earnings per share for the quarter, missing the consensus estimate of N/A by -0.07p.
Is Arecor Therapeutics PLC overvalued?
According to Wall Street analysts Arecor Therapeutics PLC’s price is currently Overvalued.
Does Arecor Therapeutics PLC pay dividends?
Arecor Therapeutics PLC does not currently pay dividends.
What is Arecor Therapeutics PLC’s EPS estimate?
Arecor Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arecor Therapeutics PLC have?
Arecor Therapeutics PLC has 37,756,600 shares outstanding.
What happened to Arecor Therapeutics PLC’s price movement after its last earnings report?
Arecor Therapeutics PLC reported an EPS of -0.07p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 19.31%.
Which hedge fund is a major shareholder of Arecor Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AREC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arecor Therapeutics PLC Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.33%
12-Months-Change
Fundamentals
Return on Equity
-204.29%
Trailing 12-Months
Asset Growth
-49.35%
Trailing 12-Months
Company Description
Arecor Therapeutics PLC
Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioMedica
―
Fusion Antibodies Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---